Characteristics | All patients (n=455) | 2010 ACR/EULAR+ (n=353) | 1987 ACR+ (n=310) | Visser+ (n=254) |
---|---|---|---|---|
Demographic variables | ||||
Age (years, mean (SD)) | 52 (13) | 52 (13) | 53 (12) | 51 (12) |
Women (% of patients) | 69 | 71 | 70 | 75 |
Disease duration (months, mean (SD)) | 5.6 (5.5) | 5.5 (5.0) | 5.6 (5.0) | 5.8 (4.9) |
SJC | 5 (3–10) | 6 (3–11) | 7 (4–11) | 6 (3–10) |
TJC | 5 (2–9) | 6 (3–10) | 6 (3–10) | 5 (3–8) |
DAS28 score (mean (SD)) | 4.8 (1.3) | 5.0 (1.2) | 5.2 (1.2) | 4.9 (1.1) |
HAQ score (range 0–3) | 1.13 (0.63–1.63) | 1.13 (0.75–1.75) | 1.25 (0.75–1.75) | 1.13 (0.75–1.63) |
RA according to ACR/EULAR (%) | 353 (77.6) | 100.0 | 89.4 | 97.6 |
RA according to 1987 ACR (%) | 310 (68.1) | 78.5 | 100.0 | 84.3 |
Persistent arthritis according to Visser (%) | 254 (55.8) | 70.3 | 69.7 | 100.0 |
Laboratory variables | ||||
ESR (mm/first hour) | 25 (11–38) | 26 (13–41) | 27 (15–41) | 26 (13–41) |
CRP (mg/l) | 11 (4–31) | 13 (4–35) | 15 (5–35) | 13 (4–30) |
IgM-RF positive (%) | 42.6 | 53.3 | 54.2 | 72.0 |
ACPA positive (%) | 52.0 | 66.2 | 59.4 | 87.4 |
Radiographic scores | ||||
Erosion score 0 (% of patients) | 93.4 | 92.9 | 91.0 | 91.3 |
Erosion score 1 (% of patients) | 6.8 | 7.1 | 9.0 | 8.7 |
Total Sharp score at baseline | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) |
Total Sharp score at 3 years (n=175) | 0.0 (0.0–4.0) | 1.0 (0.0–5.0) | 1.0 (0.0–4.5) | 1.0 (0.0–6.0) |
Results are shown as median (IQR) unless stated otherwise.
ACPA, anti-citrullinated protein antibody; ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, Disease Activity Score (28-joint count); ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.